Drug Trial Radar · NCT00175916
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
853
Actual
Start
Sep 2005
Primary completion
May 2019
Study completion May 2019
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).
Conditions
- Epilepsy
Interventions
Brivaracetam (ucb 34714)Drug
10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)Time frame: From Entry Visit until Last Visit (up to 162 months)
- Percentage of Participants Who Withdrew Due to an Adverse Event (AE)Time frame: From Entry Visit until Last Visit (up to 162 months)
- Percentage of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Entry Visit until Last Visit (up to 162 months)
Locations
153 sites in 26 countries. Site status is shown where the registry gives one.
935
San Francisco, California
933
Gainesville, Florida
931
Charlottesville, Virginia
509
Graz, Austria
507
Innsbruck, Austria
510
Linz, Austria
508
Vienna, Austria
506
Bruges, Belgium
513
Ghent, Belgium
974
La Louvière, Belgium
505
Leuven, Belgium
501
Edegem, Antwerpen, Belgium
515
Montignies-sur-Sambre, Chaleroi, Belgium
951
Vancouver, British Columbia, Canada
950
Montreal, Quebec, Canada
952
Québec, Quebec, Canada
545
Beroun, Czechia
543
Brno, Czechia
544
Brno, Czechia
546
České Budějovice, Czechia
519
Ostrava Trebovice, Czechia
517
Prague, Czechia
541
Prague, Czechia
542
Prague, Czechia
518
Zlín, Czechia
900
Helsinki, Finland
581
Kuopio, Finland
526
Oulu, Finland
582
Oulu, Finland
527
Seinäjoki, Finland
583
Tampere, Finland
811
Tampere, Finland
632
Angers, France
628
Béthune, France
630
Dijon, France
624
Lille, France
625
Marseille, France
623
Montpellier, France
635
Nancy, France
626
Paris, France
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.